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We aimed to compare infection rates for two 3-day antibiotic prophylaxis regimens for transrectal ultrasound-guided prostate
biopsy(TRUSgbp) anddemonstratelocalmicrobiologicaltrends.In 2008,558menand,in2009,625menhadTRUSgpb. Regimen
1 (2008) comprised 400mg Oﬂoxacin immediately before biopsy and 200mg 12-hourly for 3 days. Regimen 2 (2009) comprised
Oﬂoxacin200mg 12-hourly for3 days commencing24hours before biopsy.20/558(3.6%) men had febrile episodes with regimen
1 and 10/625 (1.6%) men with regimen 2 (P = 0.03). E. coli was the most frequently isolated organism. Overall, 7/13 (54%)
of positive urine cultures were quinolone resistant and (5/13) 40% were multidrug resistant. Overall, 5/9 (56%) patients with
septicaemia were quinolone resistant. All patients were sensitive to Meropenem. There was 1 (0.2%) death with regimen 1.
Commencing Oﬂoxacin 24 hours before TRUSgpb reduced the incidence of febrile episodes signiﬁcantly. We observed the
emergence of quinolone and multidrug-resistant E. coli. Meropenem should be considered for unresolving sepsis.
1.Introduction
Prostate cancer remains a leading cause of cancer mortality
in many Western countries [1, 2]. In the Irish context, com-
mencement of the National Cancer Control Programme for
prostate cancer will undoubtedly result in an increase in
men having transrectal ultrasound-guided prostate biopsy
(TRUSgpb) and being diagnosed with prostate cancer. The
diagnosis of prostate cancer is mainly made on TRUSgpb,
whichiscommonlyperformedandsafebutisassociatedwith
a small risk of infective complications including symptomat-
ic bacteriuria, bacteraemia, and potentially life-threatening
sepsis [3].Antibioticprophylaxisistheacceptedbest practice
for patients undergoing TRUSgpb but there is a lack of con-
sensus regarding the optimum regimen [4–6]. Bacteriuria
after TRUSgpbis decreased with antibiotic prophylaxis com-
pared with placebo [7]. Burden et al. highlight the lack of
standardized antibiotic guidelines and the general lack of ev-
idence-based practice for TRUSgpb [8].
Althoughmany antimicrobial agentsare usedinpractice,
quinolones remain the most widely used antibiotics due to
their broad spectrum activity, ease of oral administration,
good penetration of prostate tissue, and long-lasting urinary
bactericidal activity. The infection rate with antibiotic pro-
phylaxis is estimated at 5% and rate of septicaemia about
0.5–1% [9, 10]. Infective complications are similar when
comparing 1-day versus 3-day ciproﬂoxacin [11, 12]b u t
guidelines acknowledge that the choice of regimens remains
debatable [6].
We compared the rate of infective complications of our
standard antibiotic prophylaxis regimen with that of a mod-
iﬁed regimen. We also report on the current microbiological
ﬂora and antibiotic resistance in our region.
2.Methods
From January 2008 to December 2009, we prospectively re-
cruited 1183 consecutive men who had TRUSgpb indicated2 The Scientiﬁc World Journal
by an elevated serum prostate-speciﬁc antigen level and/or
a prostatic abnormality on digital rectal examination. All
patients gave consent for inclusion. Our standard antibiotic
prophylaxis protocol comprised three days of oral Oﬂoxacin
200mg 12-hourly, starting with a loading dose of 400mg
oral Oﬂoxacin administered immediately before TRUSgpb
(regimen 1). In 2008, 558 consecutive men had TRUSgpb
with regimen 1. In 2009, 625 consecutive men had TRUSgpb
with a modiﬁed regimen, comprising three days of 200mg
Oﬂoxacin 12-hourly commencing 24 hours before TRUSgpb
(regimen 2). All patients had 8–12 core biopsies using
18G needles after injecting 5–10ml of 1% lignocaine local
anaesthetic. Following TRUSgpb, patients were given verbal
andwritten instructions toattendthenearest medicalfacility
iftheyexperiencedfevers,rigors,orsymptomssuggestiveofa
urinary infection. Every patient returned to our department
for biopsy results two weeks after TRUSgpb, and every
patient was asked if they had presented to another medical
facility with infection, ensuring even patients who presented
to other medical facilities were included. Urine and blood
cultureresultsand antibioticsensitivities were obtainedfrom
the respective laboratories. Urine samples were cultured
on CLED agar and CHROMagar according to accredited
protocols.Organisms were identiﬁedusingeitherCHROMa-
gar colony colour or VITEK-2 (bioM´ erieux, France). Blood
cultures were incubated using the BacT Alert (bioM´ erieux,
France) system. Any signiﬁcant cultures were identiﬁed
using API (bioM´ erieux, France) or VITEK-2 biochemical
testing methods. Susceptibility testing was done according
to Clinical Laboratory Standards Institute criteria for all
signiﬁcant isolates. A febrile episode was deﬁned as an illness
accompanied by temperature >37.5◦C. Multidrug resistance
was deﬁned as resistance to three or more antibiotic classes
[13]. The t-test was used for statistical analysis. The criterion
for statistical signiﬁcance was a P<0.05.
3.Results
1183menhadTRUSgpb,558menwithregimen1(2008)and
625 men with regimen 2 (2009). Patient demographics were
homogeneous for both groups. Mean age of patients was
comparable between the two groups, 60 years for regimen 1
and64yearsforregimen2(P = 0.3).Meannumberofbiopsy
coreswas also comparableforbothregimens, 9forregimen 1
and10for regimen2(P = 0.99).AllpatientswereCaucasian.
The rate of repeat biopsies was comparable between the two
regimens with 84 repeat biopsies (15%) for regimen 1 and
98 repeat biopsies (16%) for regimen 2 (P = 0.8). 20/558
(3.6%) men had febrile episodes with regimen 1 compared
with 10/625 (1.6%) with regimen 2 (P = 0.03), a relative
risk reduction of 55% with regimen 2 (odds ratio = 0.44).
With regimen 1, of the 20 febrile episodes, 8 (40%) men
h a dp o s i t i v eu r i n ec u l t u r e sa n d6( 3 0 % )m e nh a dp o s i t i v e
blood cultures. 4/8 (50%) men with positive urine cultures
also had positive blood cultures. With regimen 2, of the 10
febrileepisodes,6(60%)menhadpositiveurineculturesand
4 (40%) men had positive blood cultures. 3/6 (50%) men
with positive urine cultures also had positive blood cultures.
With regimen 1, Escherichia coli (E. coli) was isolated in
100% of men with positive urine cultures, 5/8 (63%) of
which were quinolone-resistant. 2/8 (25%) E. coli isolates
were multidrug-resistant. Antibiotic resistance for E. coli is
shown in Tables 1 and 2. In 2009, E. coli were isolated in 5/6
(83%) men and Enterococcus was isolated in 1/6 men with
positive urine cultures. Multidrug-resistant E. coli strains
including one extended spectrum beta-lactamase (ESBL)
producer were isolated in 2/5 (40%) men. The one ESBL-
producingE.colistrainwasmulti-drugresistantandsensitive
only to amikacin and Meropenem. 6/558 (1.1%) men had
septicaemia with regimen 1, compared with 4/625 (0.64%)
men with regimen 2 but this was not statistically signiﬁcant
(P = 0.4). E. coli was isolated in blood culture in 5/6
(83%) men with septicaemia with regimen 1, of which 4/5
(80%) were quinolone-resistant; Enterococcus was isolated
from the sixth man. E. coli was isolated in 100% of men
with septicaemia with regimen 2, of which 1/4 (25%) was
quinolone resistant. All were sensitive to Meropenem. There
was one multidrug-resistant E. coli sepsis-related mortality
with regimen 1 (0.2%) and none with regimen 2.
4.Discussion
Although the rates of febrile episodes and bacteraemia in
both our groups of men are similar to other series, rates for
regimen 2 compared more favourably [3, 10, 14, 15]. Of all
patients with febrile episodes, 30–60% of our patients had
positive urine cultures or blood cultures, again, similar to
other reports [3, 16].
Although those men with febrile episodes may have
presented to other medical facilities, all patients returned
to our department for their biopsy results two weeks after
biopsy. At that consultation, patients were asked speciﬁcally
about any visits or admissions to other medical facilities and
data was then obtained from those facilities. Therefore, we
are conﬁdent that our data accurately reﬂects the incidence
of infection in our department.
There is no doubt that antibiotic prophylaxis has sig-
niﬁcantly decreased the infectious complications associated
with TRUSgpb. Nonetheless, infective complications still
occur, albeit rarely, and can be potentially life threatening,
as reﬂected by the death in our department in 2008.
While many urologists use quinolones for antibiotic
prophylaxis prior to TRUSgpb,there is a lack of consensus as
to thechoiceofantibiotic,dose,and duration ofprophylaxis.
Suggested regimens include single-dose ﬂuoroquinolone to
a 3-day course starting either immediately before biopsy
or a day before biopsy [6, 8, 17, 18]. Multidrug-resistant
and quinolone-resistant E. coli are increasingly prevalent in
various countries with up to 20–30% resistance reported in
England, Spain, the USA, and Taiwan [15, 19–21]. Because
of geographical variation in microbiological ﬂora, local
bacterial prevalence and resistance proﬁles are necessary to
facilitatespeciﬁctailoringofantibioticprophylaxisregimens.
The need to individualize regimens to the microbiological
patterns of each region, perhaps, contributes to the lack of
consensus of the subject.The Scientiﬁc World Journal 3









Amoxicillin 5 (63%) 2 (40%) 7 (54%)
Coamoxiclav 3 (38%) 1 (20%) 5 (38%)
Oﬂoxacin 5 (63%) 2 (40%) 7 (54%)
Gentamicin 2 (25%) 2 (40%) 4 (31%)
Amikacin 2 (25%) 1 (20%) 3 (23%)
3rd-generation
cephalosporin§ 0 (0%) 1 (20%) 1 (8%)
Meropenem 0 (0%) 0 (0%) 0 (0%)
§3rd-generation cephalosporin either ceftriaxone or cefotaxime.









Amoxicillin 3 (60%) 3 (75%) 6 (67%)
Coamoxiclav 1 (20%) 2 (50%) 3 (33%)
Oﬂoxacin 4 (80%) 1 (25%) 5 (56%)
Gentamicin 2 (40%) 1 (25%) 3 (33%)
Amikacin 2 (40%) 0 (0%) 2 (22%)
3rd-generation
cephalosporin§ 0( 0 % ) 0( 0 % ) 0( 0 % )
Piperacillin/
Tazobactam 0( 0 % ) 0( 0 % ) 0( 0 % )
Meropenem 0 (0%) 0 (0%) 0 (0%)
§3rd-generation cephalosporin either ceftriaxone or cefotaxime.
The diﬀering infection rates between our two regimens
are probably explained by the pharmacokinetics and bio-
availability of oral Oﬂoxacin, which reaches peak plasma
concentration 1.5–2 hours after administration [22]. If
bacterial seeding occurs during or immediately after biopsy,
then peak plasma concentration of antibiotic is necessary
at the time of biopsy. With regimen 1, where the ﬁrst dose
was immediately before biopsy, peak plasma concentration
would be subtherapeuticat the time of biopsy. With regimen
2, commencing Oﬂoxacin 24 hours prior to biopsy, peak
plasma concentration would have been achieved at the time
of biopsy, explaining the reduction in the rate of infection
and septicaemia. Nonetheless, 3/4 patients with septicaemia
in regimen 2 were quinolone sensitive (Table 2), which on
retrospective questioning was established to be due to lack
of compliance. Peak plasma concentration for Oﬂoxacin
is reached within two hours; therefore, commencing pro-
phylaxis two hours before biopsy would have been ideal.
However, we anticipated problems with compliance with
instructions to commence antibiotic prophylaxis two hours
prior to TRUSgpb; therefore, we elected to commence pro-
phylaxis 24 hours before biopsy.
In addition to quinolone resistance, we observed re-
sistance to aminoglycosides (Gentamicin and Amikacin,
Tables 1 and 2), traditionally regarded as the antibiotic of
choice for gram-negative infections. Third-generation ceph-
alosporins showed low levels of resistance and would repre-
sent a good ﬁrst-line choice. We accept that ﬁrm conclusions
about changing microbiological ﬂora cannot be drawn
from this study; however, the spectrum and prevalence of
antibiotic resistance is of interest and importance.
In this study, our patients were not screened for risk
factors, for example, previous antibiotic exposure, previous
hospital admissions or surgery, recent foreign travel, infec-
tions, in particular, urinary tract infections, obesity, diabetes
mellitus, and residence in nursing homes [23]. Risk proﬁling
may identify patients who require additional or alternative
prophylaxis, and we have since commenced a further study
screening for risk factors. Although, in this study, there
was only one culture positive for ESBL E. coli,E S B Li n f e c -
tions and multidrug resistance have been recognized as
a growing worldwide problem in the community and in
hospitals. The high frequency of multidrug resistance among
ESBL-producing strains greatly limits the possibilities of
administering an adequate prophylactic regimen to these
patients [24]. As prevalence increases, it may be necessary to
introduce additional risk reduction measures, for example,
rectal swabs [25] to screen for pathogens including ESBL
prior to TRUSgpb to allow better antibiotic selection for
these patients. This prospective study was not randomised
and nonblinded, which the authors accept as a limitation.
However, the authors feel the prospective consecutive nature
of recruitment meant there was no selection bias. The biopsy
technique, number of cores, and patient population were
comparable for both groups eliminating further con-
founders. A further limitationi st h es m a l ln u m b e ro ff e b r i l e
adverse events. However, the total number of patients who
had TRUSgpb is large and the authors feel that this data
provides useful insight into the microbiological proﬁle of
our region and adds to the existing data on emerging global
trends. The authors accept that data now exists showing a
single preoperative dose of ﬂuoroquinolone to be compara-
ble to 3-day regimens [12]; however, many units still employ
a short course for prophylaxis and there is a lack of overall
consensus on the most appropriate regimen.
The commonest bacteria isolated in our region were
E. coli. Commencing Oﬂoxacin prophylaxis 24 hours prior
to TRUS biopsy was associated with fewer febrile and
septicaemic episodes, although the latter was not statistically
signiﬁcant. Quinolone and multidrug-resistant E. coli are
emerging among our patients. The overall rate of infection
and septicaemia is low and TRUSgpb remains a safe proce-
dure. However, the microbiological trends are striking and
important.Giventheoveralllowincidenceoffebrileepisodes
and septicaemia with Oﬂoxacin prophylaxis, quinolones
remain a good choice of antibiotic for prophylaxis; however,
clinicians should consider possib l er e s i s t a n c ei nf e b r i l ep a -
tients following TRUSgpb.
5.Conclusion
It is important for centres to be aware of local microbiolog-
ical trends and antibiotic resistance. When treating a septic4 The Scientiﬁc World Journal
patient following-TRUSgpb, we recommend intravenous
third-generation cephalosporin, for example, ceftriaxone
or cefotaxime as ﬁrst-line therapy (Table 2). Consideration
should be given to using Meropenem for sepsis unresponsive
to ﬁrst-line intravenous antibiotics.
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